NCT06881823 - Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

June 29, 2026

Primary Completion Date

March 31, 2030

Study Completion Date

June 1, 2033

Conditions

Prostate Cancer

Interventions

DRUG

AAA602

\[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.

DRUG

AAA802

\[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion

DRUG

Gallium (68Ga) gozetotide

Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.

DRUG

Piflufolastat (18F)

Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.

DRUG

Flotufolastat F 18

Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.

DRUG

18F-PSMA-1007

Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.